as previously described (i0) using a I0 mM TNBS solution (Pierce Chemical Co., Rockford, Ill.) in phosphate-buffered saline, pH 7.4.
All other compounds were covalently bound to cells using haptens in the form of an acyl azide as previously described for NIP-AGG ( 11, 14, 15) . These compounds included: N-(3-nitro-4-hydroxy-5-iodophenylacetyl)-B-alanylglycylglycyl (NIP-AGG) azide; N-(3-nitro-4-hydroxyphenylacetyl)-flalanylglycylglycyl (NP-AGG) azide; N-(3-nitro-4-hydroxy-5-iodophenylacetyl) (NIP) azide; and N-(2,4,6-trinitrophenyl)-fl-alanyglycylglycyl (TNP-AGG) azide.
In Vitro Cell Culture and Assay for Cytotoxic Cells. Splenic lymphocytes were sensitized in vitro with chemically modified spleen cells in supplemented RPMI 1640 media as previously described (11) . After a 5 day incubation the cells were harvested and their cytotoxic activity measured as previously described (10) . Nonspecific lysis of modified target cells was determined from the amount of ~ICr released from the appropriate 51Cr-labeled target cells, incubated for 4 h with effector cells which had been incubated 5 days with no stimulators, divided by the maximum 5~Cr released by targets that had been frozen, and thawed repeatedly.
Results
Spleen cells from C57BL/10 mice were sensitized in vitro with autologous spleen cells modified with TNBS or with the acyl azide of TNP-AGG. The effector cells generated 5 days later were assayed on 5~Cr-labeled L5MF-22 (H-2 ~ lymphoma target cells modifed with either TNBS or TNP-AGG acyl azide. The results of five independent experiments (Table I) indicate that effector cells sensitized with autologous TNP-modified cells which consistently lysed H-2-matched, TNP-modified targets never lysed H-2-matched, TNP-AGG-modified target cells. It was demonstrated in four of the five experiments that TNP-AGGmodified targets were capable of being lysed, since effectors generated by sensitization with TNP-AGG-modified autologous cells lysed H-2-matched, TNP-AGG-modified target cells. A variable degree of lysis was obtained from experiment to experiment when these same effectors were tested on H-2-matched, TNP-modified targets. This degree of lysis ranged from 75 (exp. 5-387) to 6% (experiment 5-439) of the lysis obtained on TNP-AGG-modified targets. It is noteworthy that sensitization against autologous cells modified with TNP-AGG acyl azide was always weaker than with cells modified with TNBS.
In another series of experiments the specificity of C57BL/10 cytotoxic effector cells was investigated as a function of sensitization with autologous spleen cells modified with the acyl .azides of NIP-AGG, NP-AGG, or NIP. The results of four independent experiments are summarized in Table II . In all cases effector cells sensitized with autologous NIP-AGG-modified spleen cells lysed H-2-matched, NIP-AGG-modified tumor targets to a greater extent than tumor targets modified with the closely related acyl azides of NP-AGG or NIP. Tumor target cells modified with TNP-AGG were not lysed to any appreciable extent by these effectors.
NP-AGG-modified autologous cells were only marginally immunogenic as sensitizing cells since weak responses were detected in only two out of four experiments. In experiments 5-451 and 5-413, in which sensitization to NP-AGGmodified cells was obtained, variable cross-reactivity was observed with NIP-AGG-modified targets, and no cross-reactivity was obtained with NIP-modified targets.
Sensitization of C57BL/10 spleen cells with NIP-modified autologous cells generated effectors which lysed NIP-modified targets in all four experiments. 
II

In Vitro Induction of Cytotoxicity of C57BLH O Spleen Cells by NIP-A GG-, NP-A GG-, or NIP-Modified Spleen Cells to NIP-A GG-, NP-A GG-, or NIP-Modified L5MF-22 Tumor
Target Cells No lysis by these effectors was detected on NP-AGG-modified targets in any of the experiments. These effectors clearly lysed NIP-AGG-modified targets only in experiment 5-413. In order to further characterize the specificity of the cytotoxic lymphocytes, cold target inhibition experiments were performed in which nonradioactive cells modified with these reagents were used to block the effector phase of the CML (Table III) 45.6 ± 2.1%; section B, effector cell lysis of: (a) NIP-AGG-raodified L5MF-22 targets, 27.6 ± 2.9%; (b) NP.AGG-raodified LSMF-22 targets, 9.5 ± 2.3; (c) NIP modified L5MF-22 targets, (-0.3 -+ 3.6). * Inhibitor cells were preineubated for 30 rain at 37°C with the effector cells before addition of s'Cr-labeled target cells.
experiment, but they were not effective blockers for cytotoxic cells generated by sensitization with NIP-AGG-modified cells when assayed on NIP-AGG-modified targets (see footnote of Table III) .
Discussion
The results presented in this report demonstrate that these cytotoxic lymphocytes recognize more than just the dominant terminal feature of the modifying agent or '~hapten." In Table I , data are presented showing that cytotoxic lymphocytes generated by sensitization of splenic lymphocytes with TNP-modifled autologous spleen cells lysed H-2-matched, TNP-modified target cells but not modified target cells in which the TNP group was separated from the cell surface by an alanylglycylglycyl tripeptide spacer. H-2-matched, TNP-AGGmodified nonradioactive targets did not inhibit the lysis of TNP-modified targets by TNP-self-sensitized effector cells (Table III) . Such results are compatible with previous findings in the chemically modified CML model in which cytotoxic T lymphocytes were generated in vitro by sensitization with chemically modified autologous cells (10, 11, 13) . These findings include the observations that: (a) H-2 homology is required between stimulator and target cells (10, 11, 13) ; (b) TNP-modified and NIP-AGG-modified stimulating cells generate clones of effectors which can distinguish between these two modifying agents (11); (c) cold target inhibition can occur only when the competing, nonradioactive target cells are both H-2-matched and modified with the same agent as the stimulating cells (11, 13) ; and (d) inhibition of the lysis of modified target cells is obtained by anti-H-2 sera directed against the modified targets (16). Furthermore, the observations presented in this report are compatible with the results of Janeway and co-workers using related nitrophenyl compounds (3, 4) in which specificity was shown to include both the nitrophenyl groups and part of the protein carrier.
It was found in the current study, however, that effector cells generated by sensitization with TNP-AGG-modified stimulating cells could lyse TNP-modifled targets in some but not all experiments (see lower part of Table I ). These findings, which appear to contradict the observation that TNP-AGG-modified targets were never lysed by effector cells generated by sensitization with TNPmodified autologous stimulating cells, might be accounted for if sensitization with TNP-modified cells stimulates only clones of lymphocytes which recognize TNP and some portion of autologous H-2 cell surface products. Sensitization with TNP-AGG-modified self would be expected to activate clones of lymphocytes recognizing TNP-AGG and some part of autologous H-2 cell surface products. The cross-reactivity with TNP-modified cells could be accounted for by either the generation of a clone of effector cells which could lyse either TNP-AGG-self or TNP-self (cross-reactive clone). An alternative possibility is that sensitization with TNP-AGG-self could activate two groups of noncross-reacting clones: one which recognizes only TNP-AGG-self and a second which recognizes only TNP-self. These latter clones could be the same ones which are stimulated by TNP-self.
Effector cells generated by sensitization with NIP-AGG-modified cells consistently lysed NIP-AGG-modified targets to a greater extent than either NP-AGGor NIP-modified target cells. The lower levels of lysis detected by either NP-AGG-or NIP-modified targets could also be accounted for by at least two mechanisms. First, a clone of effector cells could be generated by sensitization with NIP-AGG which could lyse all three targets (cross-reactive clones). Second, multiple, distinct, noncross-reacting clones could be activated by NIP-AGGmodified stimulating cells. The latter possibility implies that NIP-AGG-modifled stimulating cells can stimulate clones of effector cells unable to lyse NIP-AGG-modified target cells. The blocking data shown in section B of Table III support the second possibility. Thus, the population of effector cells generated by sensitization with NIP-AGG-modified stimulating cells were capable of lysing NIP-AGG-modified target cells (27.6%) and to a lesser extent NP-AGG-modified target cells (9.5%) at an effector:target ratio of 40:1 (see footnote of Table III ). The clones of effector cells which lyse NIP-AGG-modified target cells were blocked only by NIP-AGG-modified inhibitor cells. NP-AGG-modified cells did not inhibit this reaction even at a blocker:target ratio of 160:1. This suggests the presence of separate clones of effector cells, each of which distinguishes very specifically between NIP-AGG-and NP-AGG-modified target cells even though all clones resulted from stimulation by the same modifying agent. Thus, there can be a difference in discriminating ability or fine specificity toward the modifying group for the stimulating and lytic processes. Parallel differences in discriminating power have been frequently observed by Merchant and Inman (unpublished observations) in the case of B-cell activation leading to antibody production, and subsequent hapten-directed hemolytic lysis (in complementdependent plaque assays). The inability of NIP-AGG-sensitized effector cells to lyse TNP-AGG-modified target cells demonstrates that AGG is not an exclusive immunodeterminant in this reaction. The inability of NP-AGG-modified cells to stimulate effector cells demonstrates the importance of the iodo group for immunogenicity in this system. The data presented do not support the dual receptor model for T-cell recognition in its simplest form. The intimacy or dual receptor model has been proposed as a possible expla] Ltion for the H-2 requirement for CML in the viral-infected (12) and chemically modified systems (13) . The hypothesis states that the T-cell has two distinct receptors which must be accommodated for cytotoxicity to occur. One receptor is for the simple "hapten" (a hapten as defined in the antibody system would be TNP) and the other receptor would involve recognition of a self-H-2 product on the target cell surface. If this model were valid, one would expect to see no example in which an effector cell would distinguish between a hapten coupled to a target cell surface and a hapten coupled to a target cell surface with a short flexible peptide spacer. For CML responses to TNP-modified autologous cells, this two-receptor model in its simplest form should involve the recognition of TNP hapten in one receptor and a self-H-2 cell surface product in the other receptor. An effector cell sensitized to TNP-self would be expected to kill equally well TNP-or TNP-AGG-modified target cells, since both would fulfill the requirements of possessing the hapten TNP and self-H-2 cell surface products. In order for the intimacy model to remain viable in the chemically modified CML system it is necessary to postulate that the so called hapten involves more than just TNP (which is a hapten for antibody production) and would have to include TNP plus one or more adjacent amino acids. 
